Vaxcyte Inc
PCVX33.126USD
+0.106+0.32%
Horário de mercado （ET）Cotações atrasadas em 15 min
4.27BValor de mercado
PerdaP/L TTM
Mais detalhes de Vaxcyte Inc Empresa
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
Informações da empresa
Código da empresaPCVX
Nome da EmpresaVaxcyte Inc
Data de listagemJun 12, 2020
CEOMr. Grant E. Pickering
Número de funcionários414
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 12
Endereço825 Industrial Road, Ste. 300
CidadeSAN CARLOS
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94070
Telefone16508370111
Sitehttps://vaxcyte.com/
Código da empresaPCVX
Data de listagemJun 12, 2020
CEOMr. Grant E. Pickering
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
676.65K
+3.13%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
83.56K
+6.06%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
34.31K
+21.13%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
12.60K
-28.82%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.67K
+54.06%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
8.67K
+54.06%
Mr. Jacks Lee
Mr. Jacks Lee
Independent Director
Independent Director
3.04K
--
Mr. John P. Furey
Mr. John P. Furey
Independent Director
Independent Director
3.04K
--
Dr. Olivier Brandicourt
Dr. Olivier Brandicourt
Independent Director
Independent Director
1.15K
--
Dr. Heath Lukatch, Ph.D.
Dr. Heath Lukatch, Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
676.65K
+3.13%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
83.56K
+6.06%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
34.31K
+21.13%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
12.60K
-28.82%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.67K
+54.06%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
8.67K
+54.06%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Janus Henderson Investors
11.27%
RA Capital Management, LP
9.45%
The Vanguard Group, Inc.
9.32%
Fidelity Management & Research Company LLC
8.31%
BlackRock Institutional Trust Company, N.A.
7.08%
Other
54.57%
Investidores
Investidores
Proporção
Janus Henderson Investors
11.27%
RA Capital Management, LP
9.45%
The Vanguard Group, Inc.
9.32%
Fidelity Management & Research Company LLC
8.31%
BlackRock Institutional Trust Company, N.A.
7.08%
Other
54.57%
Tipos de investidores
Investidores
Proporção
Investment Advisor
47.62%
Investment Advisor/Hedge Fund
40.88%
Hedge Fund
12.35%
Venture Capital
10.72%
Research Firm
1.95%
Private Equity
0.97%
Sovereign Wealth Fund
0.85%
Bank and Trust
0.73%
Individual Investor
0.70%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
652
151.34M
117.31%
-374.47K
2025Q1
669
149.26M
115.73%
-5.52M
2024Q4
629
143.44M
111.44%
-3.61M
2024Q3
579
138.80M
114.99%
+5.28M
2024Q2
508
125.57M
113.86%
-5.08M
2024Q1
487
122.06M
113.01%
+8.05M
2023Q4
444
106.09M
111.72%
-6.02M
2023Q3
417
110.70M
121.97%
-7.51M
2023Q2
397
109.13M
122.07%
+11.09M
2023Q1
366
92.70M
119.26%
-1.36M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Janus Henderson Investors
14.54M
11.27%
+2.77M
+23.58%
Apr 30, 2025
RA Capital Management, LP
12.19M
9.45%
+3.50M
+40.28%
Mar 31, 2025
The Vanguard Group, Inc.
12.02M
9.32%
+82.12K
+0.69%
Mar 31, 2025
Fidelity Management & Research Company LLC
10.73M
8.31%
-632.25K
-5.57%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
9.13M
7.08%
-112.81K
-1.22%
Mar 31, 2025
Wellington Management Company, LLP
6.42M
4.97%
+1.97M
+44.39%
Mar 31, 2025
Capital Research Global Investors
6.11M
4.74%
-100.42K
-1.62%
Mar 31, 2025
State Street Global Advisors (US)
4.41M
3.42%
-131.72K
-2.90%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.44M
2.66%
-429.53K
-11.11%
Mar 31, 2025
Kynam Capital Management LP
3.20M
2.48%
+863.20K
+36.94%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
ALPS Medical Breakthroughs ETF
2.84%
Harbor Health Care ETF
2.75%
SPDR S&P Biotech ETF
1.36%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
Direxion Daily S&P Biotech Bull 3X Shares
0.77%
Invesco Nasdaq Biotechnology ETF
0.47%
ProShares Ultra Nasdaq Biotechnology
0.47%
iShares Biotechnology ETF
0.42%
Nuveen ESG Small-Cap ETF
0.36%
JPMorgan Fundamental Data Science Small Core ETF
0.36%
Ver Mais
ALPS Medical Breakthroughs ETF
Proporção2.84%
Harbor Health Care ETF
Proporção2.75%
SPDR S&P Biotech ETF
Proporção1.36%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.85%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.77%
Invesco Nasdaq Biotechnology ETF
Proporção0.47%
ProShares Ultra Nasdaq Biotechnology
Proporção0.47%
iShares Biotechnology ETF
Proporção0.42%
Nuveen ESG Small-Cap ETF
Proporção0.36%
JPMorgan Fundamental Data Science Small Core ETF
Proporção0.36%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
